Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganetespib and carboplatin with niraparib maintenance versus standard platinum-based chemotherapy with niraparib in platinum-sensitive relapsed ovarian cancer
2017-004058-40Phase 2Completed
- Sponsor
- KU Leuven
- Start
- Aug 2018
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ganetespib, niraparib and carboplatin in ovarian cancer (3 arms), sponsored by KU Leuven. Primary endpoint: Progression-free survival by RECIST 1.1. Started Aug 2018; status: completed.
02
Drugs
ganetespibniraparibcarboplatin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2017-004058-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004058-40.